Global stocks: 3 solid buys - Apple Inc, Thomson Reuters Corp and Johnson & Johnson

Published September 13, 2018

Share prices are a broader picture of investor sentiment and demand-supply, and a direct representation of what is happening inside a company or an instrument. Whether it is a bite of an APPLE, a news coverage by the service provider Thomson Reuters or the Fortune 500 listed Johnson & Johnson, everything is reflected in their share prices. With the use of technical analysis we analyze how seriously or not investors think about these companies - shown in the charts below.

Apple Inc (AAPL.US) Close: 221.07


Apple Inc broke out of the upper trendline of the rising trend channel in the medium term. This signals increasing optimism among investors and indicates continued rise. The rise in stock price is supported by high volume and any correction is supported by low volume. This indicates a positive volume balance. The stock is currently under its short term high of 228 and a break out from that level may initiate new buying. However, in case of a correction, there is support around 190.
Apple Inc came up with new announcements on Wednesday September 12, and it would be interesting to see how investors and traders will react to it in coming trading sessions.
This stock is listed on NASDAQ and is traded in USD.
Investtech's recommendation: Buy

 

Thomson Reuters Corp (TRI.US) Close: 45.22 (+0.65)


Thomson Reuters Corp shows strong development within a rising trend channel in the medium term. Rising trends indicate that the company experiences positive development and that buy interest among investors is increasing. The stock has broken up through the resistance at dollar 44.90. This predicts a further rise. There is support around 42.50 and resistance around 48.
RSI is above 70 after a good price increase the past weeks. The stock has strong positive momentum and positive volume balance. Further increase in stock price is indicated.
Thomas Reuters Inc is listed on NYSE and is traded in USD.
Investtech's recommendation: Buy

 

Johnson & Johnson (JNJ.US) Close: 139.36 (+0.85)


Pharmaceutical giant Johnson & Johnson is in a rising trend channel. This indicates that investors are positive about the company's future and have steadily paid higher prices to buy stock in the company. Further rise in price is suggested.
Currently the stock is trading around its earlier resistance of 136 and is inching towards its previous all-time-high of 148. A breakout above that level will initiate a new buy signal.
The stock now has support around 133-136 levels. Volume balance indicator is very positive, something that indicates that buyers outnumber sellers. Also, the momentum indicator RSI is over 70 that suggests strong underlying momentum in the stock. Together these indicators support the rising trend in Johnson and Johnson.
The stock is traded on NYSE and is traded in USD.
Investtech's recommendation: Buy

 

Our analysis is majorly based on trend, as it is said, ‘trend is your best friend’, with more focus on the medium term chart. We also take into account price formations and volume, and momentum indicators. More can be read about Investtech's research at www.thetrendbible.com.

Note: These stocks are traded in currency based on the country they are listed on.

 

 

The analyses are based on closing price as per September 12, 2018.

Skrevet av

Kiran R. Shroff
Analytiker
i Investtech

"Investtech analyserer psykologien i markedet og gir deg konkrete tradingforslag hver dag."

Espen Grønstad
Partner & Senior Advisor - Investtech
 


Investeringsanbefalingen(e) er utarbeidet av Investtech.com AS ("Investtech"). Investtech garanterer ikke fullstendigheten eller riktigheten av analysen. Eventuell eksponering i henhold til rådene / signalene som fremkommer i analysene står fullt og helt for investors regning og risiko. Investtech er ikke ansvarlig for noe tap, verken direkte eller indirekte, som oppstår som en følge av bruk av Investtechs analyser. Opplysninger om eventuelle interessekonflikter vil alltid fremgå av investeringsanbefalingen. Ytterligere informasjon om Investtechs analyser finnes på informasjonssiden.


Investeringsanbefalingen(e) er utarbeidet av Investtech.com AS ("Investtech"). Investtech garanterer ikke fullstendigheten eller riktigheten av analysen. Eventuell eksponering i henhold til rådene / signalene som fremkommer i analysene står fullt og helt for investors regning og risiko. Investtech er ikke ansvarlig for noe tap, verken direkte eller indirekte, som oppstår som en følge av bruk av Investtechs analyser. Opplysninger om eventuelle interessekonflikter vil alltid fremgå av investeringsanbefalingen. Ytterligere informasjon om Investtechs analyser finnes på informasjonssiden.

Titlex

OK